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Mitochondrial preparations from endocrine tissues were incubated with radioactive cholesterol and the effect of hydroxyl- 
ated metabolites of 23,24-dinor-5-cholen-38-01 (23,24-dinor-S-cholene-3B,20-diol and 23,24-dinor-5-cholene-38,21-diol) 
on the production of pregnenolone was measured. These compounds are intermediates in an alternative, sesterterpene 
pathway for steroid hormone biosynthesis. It was found that these materials, like the analogous ide-chain-hydroxylated 
derivatives of cholesterol (20a-hydroxycholesterol and 22S-hydroxycholesterol), inhibit cholesterol side-chain cleavage. 
The possibility that there could be a control mechanism whereby metabolites of 23,24-dinor-S-cholen-3&01 inhibit 
steroidogenesis occurring by the cholesterol pathway is discussed. 
Pregnenolone; Steroid hormone synthesis; Steroidogenesis inhibitor; 23,24-Dinor-S-cholen-3/?-01; (Ovary, Adrenal) 
1. INTRODUCTION 
It has been demonstrated, at least in vitro, that 
steroidogenesis can occur by a sesterterpene 
pathway in addition to the conventional pathway 
through cholesterol [l]. In this pathway, a 
sesterterpene hydrocarbon (five isoprene units) is 
formed and subsequently converted to steroid hor- 
mones via the intermediate 23,24-dinor-5-cholen- 
3,&01 (Guneribol) (scheme 1, I). Rat testes and 
adrenals can convert both 23,24-dinor-Scholen- 
3,&01 and cholesterol to steroid hormones in vitro. 
The conversion of the former occurs in the micro- 
somal fraction, that of cholesterol taking place in 
the mitochondrial fraction [2,3]. 
23,24-Dinor-5-cholene-3fl,20-diol (II) and 23,24- 
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dinor-5-cholene-3,8,21-diol (III), metabolites of 
23,24-dinor-5-cholen-3,&ol, are biosynthesised 
from radioactive acetate in vitro [1,4,5]. The con- 
version of 23,24-dinor-5-cholen-3,&ol to the diols 
(II, III) occurs in the mitochondrial fraction of rat 
adrenals [3], but they do not undergo side-chain 
cleavage in these organelles (cf. [6,7]). However, 
23,24-dinor-5-cholene-3,8,20-diol is converted to 
steroid hormones by bovine adrenal homogenates 
[l], presumably by the microsomes [2,3]. 
23,24-Dinor-5-cholene-3,8,20-diol is also converted 
to cortisol by the guinea-pig in vivo [8]. 
The initial step in the conversion of cholesterol 
to steroid hormones is side-chain cleavage in the 
mitochondria to form pregnenolone. Side-chain- 
hydroxylated derivatives of cholesterol, e.g. 2ocU- 
hydroxycholesterol (IV) [9- 1 l] and 229hydrocho- 
lesterol (V) [12] inhibit this conversion. Evidence is 
now presented that 23,24-dinor-5-cholene-3,8,20- 
diol and 23,24-dinor-5-cholene-3,8,21-diol also in- 
hibit the side-chain cleavage of cholesterol. The 
possible significance of this finding for the control 
of steroidogenesis considered. 
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Scheme 1. Structural formulae of I-V. 
2. MATERIALS AND METHODS 
[7(n)-“HICholesterol (spec. act. 185 GBq/mmol) was pur- 
chased from Amersham International (Amersham, Bucks). 
Syntheses of 23,24-dinor-5-cholen-3,f3-ol, 23,24-dinor-5- 
cholene-3j3,20-diol and 23,24-dinor-S-cholene-3&21-diol, 
general procedures and sources of materials have been de- 
scribed [2,4]. The solvent systems used for thin-layer 
chromatography were toluene-ethyl acetate [A, 3 : 2 (v/v); B, 
1: 4 (v/v)] and cyclohexane-acetone [C, 7 : 1 (v/v)]. 
Tissue (0.3-2 g) was homogenised by hand, using a glass 
homogeniser, in sucrose solution (0.25 mol/l, 2 ml/g tissue). 
The homogenate was centrifuged at 800 x g for 10 min and the 
supernatant again centrifuged at 10500 x g for 25 min. The 
residue obtained was washed by dispersion in sucrose solution 
(0.25 mol/l, 5 ml) and centrifugation, first for 10 min at 800 x 
g (when the residue was discarded) and then for 15 min at 
10500 x g. This washing procedure was repeated and the 
10500 x g residue, referred to as the mitochondrial fraction, 
was suspended in 5 ml sucrose (0.25 mol/l) containing CaC12 
(0.01 mol/l) and b-cyano-4,4,17o-trimethyl-17-hydroxy- 
androst-5-en-3-one (cyanoketone, 50 pmol/l). The homogenisa- 
tion and centrifugation steps were carried out at 4°C. Portions 
of the mitochondrial suspension (1 ml) were incubated at 37°C 
for 0.5 h in phosphate buffer (0.1 mol/l, pH 7.4, 1 ml) contain- 
ing [7(n)-3H]cholesterol [370 kBq, 0.77 pg in propylene glycol 
(5Opg)] and NADPH (1.3 mmol/l). With some incubations 
23,24-dinor-5-cholen-3&ol, 23,24-dinor-5-cholene-3,&20-diol 
or 23,24-dinor-5-cholene-3fl,21-diol (60rmol/l) were added to 
assess their effect on the cholesterol side-chain-cleavage ac- 
tivity. 
Steroids were extracted from the incubations [2] and carrier 
steroid, pregnenolone (0.25 pmol), was added to the extracts 
which were then chromatographed in system A. The area cor- 
responding to pregnenolone was eluted, acetylated and 
rechromatographed sequentially in systems B and C. Further 
pregnenolone acetate (150 rmol) was added to a portion of the 
eluted pregnenolone acetate area from the final chromatograms 
and crystallised to constant specific activity, which was con- 
sidered to be achieved when the values for three consecutive 
crops agreed to within f 5%. The specific activities are 
reported as means * SD. 
A mitochondrial preparation from the adrenal of a patient 
with an aldosterone secreting tumour and homogenates of 
human ovarian tissue were prepared and incubated with 
23,24-dinor-5-[7a-‘H]cholen-3&ol asdescribed [2,3]. 
3. RESULTS 
The conversion of cholesterol to pregnenolone 
was inhibited by 23,24-dinor-5-cholene-3,f3,20-diol 
and 23,24-dinor-5-cholene-3fl,21-diol (table 1). 
The 3,&,21-diol was a more effective inhibitor than 
the 3,B,20-diol. The parent compound 23,24-dinor- 
5-cholen-3@-ol (I) also inhibited cholesterol side- 
chain cleavage (table 1, expt 1) but to a lesser ex- 
tent than either of the diols (11,111). 
23,24-Dinor-5-cholene-3,&,20-diol was isolated 
from the human ovarian incubations and 
crystallised to constant specific activity (314 f. 
7.2 dpm/,umol). The crystals obtained were com- 
bined, acetylated and again crystallised to constant 
specific activity (305 f 9.7 dpm/pmol). From a 
second experiment the specific activities were 
found to be 376 + 13.7 and 401 f 4.0 dpm/pmol 
for 23,24-dinor-5-cholene-3,B,20-diol and its 
acetate, respectively. 23,24-Dinor-5-cholene- 
3P,21-diol was also isolated from these incuba- 
tions. From the first experiment he specific ac- 
tivities amounted to 105 f 2.7 and 128 f 
1.3 dpm/pmol for the free steroid and its 
diacetate, respectively. From the second experi- 
ment the corresponding values were 116 + 3.4 and 
120 f 5.0 dpm/pmol for the free steroid and its 
diacetate. 
23,24-Dinor-5-cholene-3,&,20-diol was isolated 
from the human adrenal mitochondrial incubation 
and crystahised to constant specific activity (703 k 
32.5 dpm/pmol); the crystals were combined, 
acetylated and again crystallised to constant 
specific activity (778 f 12.4 dpm/pmol). 
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May 1988 
The effect of various steroids on pregnenolone production by mitochondrial preparations incubated with 
cholesterol 
Expt 
no. 
Additions Pregnenolone Total radio- Percentage 
mean specific activity in inhibition 
activities of pregnenolone 
crops (dpm/pmol) (dpm) 
(SD) 
(1) Bovine corpus none 437 (4.6) 7.8 x lo4 _ 
luteum 23,24-dinor-5-cholen-3fi-ol 319 (12.8) 5.0 x 104 35.9 
23,24-dinor-S-cholene-3/3,20-diol 162 (4.2) 3.0 x 104 61.5 
23,24-dinor-5-cholene-3@,21-diol 99.4 (4.7) 1.9 x 104 75.6 
(2) Bovine corpus none 36.5 (1.2) 6.3 x 10’ - 
luteum 23,24-dinor-5-cholene-3/3,20-diol 27.2 (1.0) 4.6 x 10’ 27.0 
23,24-dinor-5-cholene-3fl,21-diol 22.7 (1.0) 3.6 x 10’ 42.9 
(3) Bovine adrenal none 2670 (111) 4.3 x 105 - 
23,24-dinor-5-cholene-3~,2Odiol 2077 (20.8) 3.0 x 105 30.2 
23,24-dinor-5-cholene-3fl,21-diol 684 (6.0) 1.3 x 105 69.8 
(4) Rat adrenal none 83.7 (0.6) 1.3 x 104 _ 
23,24-dinor-5-cholene-3fl,20-diol 46.3 (1.5) 8.1 x 10’ 37.7 
23,24-dinor-5-cholene-3,9,21-diol 39.5 (1.2) 6.2 x 10’ 52.3 
Mitochondrial preparations were incubated in phosphate buffer (0.1 mol/l, pH 7.4) containing 
[7(n)-3H]cholesterol (370 kBq, 0.8 rg), cyanoketone (25 rmol/l) and NADPH (1.3 mmol/l). With some 
indications further steroids (60 pmol/l) were added to assess their effect on pregnenolone production 
Percentage inhibition = 
control dpm - sample dpm 
x 100 
control dpm 
4. DISCUSSION 
The conversion of 23,24-dinor-5-cholen-3,&ol to
steroid hormones (e.g. testosterone or cor- 
ticosterone) takes place in, the microsomal fraction 
from rat testis and adrenals, respectively [2,3]. 
However, when 23,24-dinor-5-cholen-3,&ol is in- 
cubated with preparations of rat [3] or human 
adrenal mitochondria (above) metabolism appears 
to stop after 20- or 21-hydroxylation (cf. [6,7]). In 
this fraction these compounds may have another 
function, namely inhibition of cholesterol side- 
chain cleavage and thereby regulation of the pro- 
duction of active hormones by the C27 pathway. 
These inhibitors are analogous to the side-chain- 
hydroxylated cholesterols (20-hydroxy- and 22-hy- 
droxycholesterols) which have been recognised as 
inhibitors of cholesterol side-chain cleavage [9-121. 
Sheets and Vickery [7] have also found that 23,24- 
dinor-5-cholene-3P,21-diol, named 23,24-dinor- 
cholene-3,&,22-diol to draw the structural analogy 
with 22-hydroxycholesterol, is not converted to 
pregnenolone and is an inhibitor (40%) of preg- 
nenolone production from cholesterol by a re- 
constituted cytochrome P-450,,, enzyme system. 
Hydroxylated derivatives of 23,24-dinor-5- 
cholen-3,&ol have been observed in several in- 
stances ([ 1,3-51 and here) and it is now shown that 
they can inhibit the production of pregnenolone 
from cholesterol, and thus inhibit steroid hormone 
production from cholesterol. This raises the 
possibility of a control mechanism whereby, in 
cells where the sesterterpene pathway is function- 
ing to produce one steroid hormone, it may sup- 
press steroidogenesis by the cholesterol pathway. 
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